Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Conditions
Ovarian Cancer · Lung Adenocarcinoma · Endometrial Cancer · Lung Squamous Cell Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Research Site, Duarte, California, United States
Research Site, Irvine, California, United States
Research Site, La Jolla, California, United States
Research Site, Aurora, Colorado, United States
Research Site, Louisville, Kentucky, United States
Research Site, Boston, Massachusetts, United States
Research Site, Detroit, Michigan, United States
Research Site, Columbus, Ohio, United States
Research Site, Portland, Oregon, United States
Research Site, Providence, Rhode Island, United States
Research Site, Providence, Rhode Island, United States
Research Site, Houston, Texas, United States
Research Site, Fairfax, Virginia, United States
Research Site, Liverpool, Australia
Research Site, Melbourne, Australia
Research Site, Edmonton, Alberta, Canada
Research Site, London, Ontario, Canada
Research Site, Toronto, Ontario, Canada
Research Site, Montreal, Quebec, Canada
Research Site, Montreal, Quebec, Canada
Research Site, Chengdu, China
Research Site, Chongqing, China
Research Site, Guangzhou, China
Research Site, Guangzhou, China
Research Site, Jinan, China
Research Site, Xi'an, China
Research Site, Zhengzhou, China
Research Site, Berlin, Germany
Research Site, Essen, Germany
Research Site, Freiburg im Breisgau, Germany
Research Site, Hanover, Germany
Research Site, Leipzig, Germany
Research Site, Mannheim, Germany
Research Site, Regensburg, Germany
Research Site, Haifa, Israel
Research Site, Ramat Gan, Israel
Research Site, Hidaka-shi, Japan
Research Site, Kashiwa, Japan
Research Site, Kōtoku, Japan
Research Site, Sunto-gun, Japan
Research Site, Tokyo, Japan
Research Site, Seoul, South Korea
Research Site, Seoul, South Korea
Research Site, Barcelona, Spain
Research Site, Madrid, Spain
Research Site, Madrid, Spain
Research Site, Málaga, Spain
Research Site, Taichung, Taiwan
Research Site, Tainan, Taiwan
Research Site, Taipei, Taiwan
Research Site, Taipei, Taiwan
Research Site, Ankara, Turkey (Türkiye)
Research Site, Ankara, Turkey (Türkiye)
Research Site, Ankara, Turkey (Türkiye)
Research Site, Istanbul, Turkey (Türkiye)
Research Site, Cambridge, United Kingdom
Research Site, Glasgow, Scotland, United Kingdom
Research Site, London, United Kingdom
Research Site, London, United Kingdom
Research Site, Sutton, United Kingdom
Study leads
Funda Meric-Bernstam, MD
Principal Investigator
UT MD Anderson Cancer Center